Anixa Biosciences Inc

ANIX

Company Profile

  • Business description

    Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

  • Contact

    3150 Almaden Expressway
    Suite 250
    San JoseCA95118
    USA

    T: +1 408 708-9808

    https://www.anixa.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 October 2026

    Employees

    4

Stocks News & Analysis

stocks

ASX energy share undervalued ahead of earnings

Pricing strength outweighs temporary production headwinds.
stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks

This onetime AI market darling is now surprisingly undervalued

This AI leader qualifies as a GARP stock today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.4069.700.77%
CAC 408,634.03124.391.46%
DAX 4026,077.62448.381.75%
Dow JONES (US)53,076.02590.991.13%
FTSE 10010,846.1621.89-0.20%
HKSE26,009.40124.970.48%
NASDAQ25,775.21401.361.58%
Nikkei 22563,754.90607.12-0.94%
NZX 50 Index13,774.9375.650.55%
S&P 5007,572.4382.711.10%
S&P/ASX 2009,019.3070.300.79%
SSE Composite Index3,809.6622.60-0.59%

Market Movers